Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.
2.

Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.

McCracken JT, McGough JJ, Loo SK, Levitt J, Del'Homme M, Cowen J, Sturm A, Whelan F, Hellemann G, Sugar C, Bilder RM.

J Am Acad Child Adolesc Psychiatry. 2016 Aug;55(8):657-666.e1. doi: 10.1016/j.jaac.2016.05.015. Epub 2016 Jun 3.

3.

Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.

Storebø OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, Nilausen TD, Magnusson FL, Zwi M, Gillies D, Rosendal S, Groth C, Rasmussen KB, Gauci D, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C.

BMJ. 2015 Nov 25;351:h5203. doi: 10.1136/bmj.h5203. Review.

4.

Changing patterns of alpha agonist medication use in children and adolescents 2009-2011.

Fiks AG, Mayne SL, Song L, Steffes J, Liu W, McCarn B, Margolis B, Grimes A, Gotlieb E, Localio R, Ross ME, Grundmeier RW, Wasserman R, Leslie LK.

J Child Adolesc Psychopharmacol. 2015 May;25(4):362-7. doi: 10.1089/cap.2014.0122. Epub 2015 Apr 28.

6.
7.

Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders.

Ming X, Mulvey M, Mohanty S, Patel V.

Adolesc Health Med Ther. 2011 Sep 30;2:105-12. doi: 10.2147/AHMT.S15672. eCollection 2011. Review.

8.

Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies.

Shier AC, Reichenbacher T, Ghuman HS, Ghuman JK.

J Cent Nerv Syst Dis. 2012 Dec 20;5:1-17. doi: 10.4137/JCNSD.S6691. Print 2013.

9.

Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns.

Hodgkins P, Setyawan J, Mitra D, Davis K, Quintero J, Fridman M, Shaw M, Harpin V.

Eur J Pediatr. 2013 Jul;172(7):895-906. doi: 10.1007/s00431-013-1969-8. Epub 2013 Feb 26.

10.

Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial.

Fagermoen E, Sulheim D, Winger A, Andersen AM, Vethe NT, Saul JP, Thaulow E, Wyller VB.

BMC Res Notes. 2012 Aug 7;5:418. doi: 10.1186/1756-0500-5-418.

11.

The treatment of severe child aggression (TOSCA) study: Design challenges.

Farmer CA, Arnold LE, Bukstein OG, Findling RL, Gadow KD, Li X, Butter EM, Aman MG.

Child Adolesc Psychiatry Ment Health. 2011 Nov 10;5(1):36. doi: 10.1186/1753-2000-5-36.

12.
13.

Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates.

Decamp E, Clark K, Schneider JS.

Eur J Neurosci. 2011 Sep;34(6):1018-22. doi: 10.1111/j.1460-9568.2011.07815.x. Epub 2011 Aug 23.

14.

ADHD in children and adolescents.

Keen D, Hadijikoumi I.

BMJ Clin Evid. 2011 Feb 4;2011. pii: 0312. Review.

15.

Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD.

Kollins SH, Jain R, Brams M, Segal S, Findling RL, Wigal SB, Khayrallah M.

Pediatrics. 2011 Jun;127(6):e1406-13. doi: 10.1542/peds.2010-1260. Epub 2011 May 9.

16.

The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders.

Winstanley CA.

Br J Pharmacol. 2011 Oct;164(4):1301-21. doi: 10.1111/j.1476-5381.2011.01323.x. Review.

17.

Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.

Wilens TE, Spencer TJ.

Postgrad Med. 2010 Sep;122(5):97-109. doi: 10.3810/pgm.2010.09.2206. Review.

18.

Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder.

Cannon M, Pelham WH, Sallee FR, Palumbo DR, Bukstein O, Daviss WB.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):511-7. doi: 10.1089/cap.2009.0008.

19.

Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):501-10. doi: 10.1089/cap.2008.0152.

20.

An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.

Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle RL, Martelon M, Brodziak K.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):485-92. doi: 10.1089/cap.2008.0125.

Supplemental Content

Support Center